WEBULL
WebtradeDownload

How Positive Trial Results At Amgen (AMGN) Have Changed Its Investment Story

Simply Wall St · 2d ago
  • Amgen reported in late October 2026 that Phase 3 data for IMDELLTRA in extensive stage small cell lung cancer and Tezspire in eosinophilic esophagitis showed statistically significant efficacy benefits versus standard care or placebo, with safety profiles consistent with prior use.
  • The breadth of late stage oncology and immunology results, combined with ongoing work in rare autoimmune diseases like Sjögren's and IgG4-Related Disease, underscores how Amgen's pipeline spans several of the therapeutic areas that underpin its long term revenue mix expectations.
  • We will now look at how Amgen's broader investment narrative is affected by the IMDELLTRA Phase 3 survival data.

Scan how Amgen’s clinical wins and compliance setbacks compare with peers by reviewing 29 resilient stocks with low risk scores that pair sturdier risk profiles with disciplined execution in regulated markets.

Amgen Investment Narrative Recap

To remain a shareholder in Amgen, you need to believe the drug portfolio in cardiometabolic, oncology and rare disease can continue offsetting pricing pressure and biosimilar erosion. The key short term swing factor is execution on late stage launches such as IMDELLTRA and TEZSPIRE, which contribute to earnings power and help support debt on the balance sheet.

The FDA warning letter on Vectibix adds compliance risk but does not change that central thesis if it is contained to promotion practices. The bigger operational concern remains drug pricing pressure and competition in older franchises, so the main watchpoint is whether new oncology and autoimmune assets ramp smoothly enough to maintain overall growth.

The FDA letter regarding Vectibix promotion is the most relevant recent development because it speaks directly to regulatory risk at a time when Amgen is relying on oncology for future cash flows. The video in question omitted boxed warning risks and full indication details, which prompted a firm response from the Office of Prescription Drug Promotion.

For investors focused on catalysts, the issue is whether Amgen tightens its promotional review processes quickly and avoids broader fallout that could distract from launches such as IMDELLTRA and TEZSPIRE. Effective follow through on corrective communications, together with continued presentation of detailed trial data, will matter if you prioritize execution quality as much as pipeline breadth.

Amgen's current analyst narrative points to revenues of $42.4b and earnings of $10.7b by 2029, based on an assumed 3.6% yearly increase in revenue and an earnings rise of about $2.0b from $8.7b today.

Uncover why Amgen's fair value indicates a 16% potential downside to its current price, leaving little room for error.

NasdaqGS:AMGN 1-Year Stock Price Chart
NasdaqGS:AMGN 1-Year Stock Price Chart

Exploring Other Perspectives

Some bearish analysts focus on regulatory risk around Amgen’s marketing practices rather than the drug data itself. Before this FDA warning, the lowest forecasts were for roughly flat sales at about US$39.0b by 2029 and earnings of US$8.6b. That view is far more cautious, and these enforcement headlines may push estimates either way, so compare several narratives yourself.

Explore 4 other Amgen fair value estimates, including one that suggests as much as 23% downside from the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking for more investment ideas beyond Amgen?

If the Amgen story has sharpened your thinking on risk, cash flows and balance sheets, you might want to scan a broader field of opportunities using the Simply Wall St Screener. These filters help you quickly narrow the universe to businesses that better fit your return goals and comfort with volatility.

  • If capital preservation and steadier price swings matter to you, start with a basket of companies flagged for resilience through the 29 resilient stocks with low risk scores.
  • Income focused investors who want yield with some quality guardrails can assess potential cash generators by reviewing a curated set of 5 dividend fortresses.
  • For those hunting for mispriced quality where the story is less crowded, consider exploring 19 high quality undiscovered gems that pair robust fundamentals with limited current attention from the market.